Britain and America have finalized a landmark trade agreement that will keep no levies on British drug exports going into the American market.
The Terms of the Deal
In exchange for the tariff guarantee, the UK has agreed to boost expenditure on drugs through the National Health Service (NHS). This move secures that tariffs on these key goods will be held at nothing for a period of the next three years.
This deal is in response to recent statements to hike duties on branded drug products, with increases discussed reaching double the cost.
"This arrangement between the United Kingdom strengthens the worldwide climate for innovative medicines and establishes long-overdue balance to transatlantic pharmaceutical trade," a release declared.
Economic Significance
Pharmaceuticals constitute one of the the United Kingdom's largest export categories to the US, which is easily the biggest buyer for major British pharmaceutical firms.
Export figures reveal that in the year to the end of last September, the UK shipped pharmaceutical products totaling £11.1bn to the US. This value made up nearly one-fifth of total UK exports in that span.
"This guarantee safeguards jobs, increases investment and sets the stage for the UK to establish itself as a global hub for biotech and pharma," a government official commented.
Detailed UK Commitments
The pact includes several key commitments from the United Kingdom:
- Revised Affordability Limit: The UK will increase the cost ceiling at which it deems new treatments to be unaffordable by 25%.
- Boosted Medicine Funding: There is a target to double total public funding on drugs from 0.3 percent of Gross Domestic Product to 0.6 percent over the coming ten years.
- Rebate Cap: The sum pharmaceutical firms must refund to the NHS to control costs will be restricted at 15%. Last year, rebates exceeded 20%.
Industry Background
This agreement takes place against a protracted dispute between the sector and the British authorities over drug pricing and approval rates.
This friction were heightened by assertions that US consumers were paying several times more for the equivalent treatments than consumers in the other developed nations.
Over the last 18 months, several large drug company projects in the UK have been paused or scrapped, while major expansions have been pledged toward projects in the United States.
A senior figure publicly accepted that the NHS needed to increase expenditure on treatments, noting that its spending on drugs had shrunk as a percentage of its total funding over the last ten years.
